Funded Startups in Pudong
All five most recent Pudong entries list undisclosed funding amounts, so comparative size across companies is not observable in the disclosed-dollar column…
All five most recent Pudong entries list undisclosed funding amounts, so comparative size across companies is not observable in the disclosed-dollar column (Guoquangzi on 2026-07-16, e-BLOT Life Sciences on 2026-07-13, UniXell Biotechnology on 2025-11-03, Jiaoying Medical on 2025-10-17, and Affinity on 2025-09-11). The temporal window is tight: rounds shown span from 2025-09-11 to 2026-07-16, with three of the five entries landing between 2025-10-17 and 2026-07-13 (Jiaoying Medical 2025-10-17, UniXell Biotechnology 2025-11-03, and e-BLOT Life Sciences 2026-07-13).
Sector and stage mix cluster heavily toward life sciences/health-related work. Four of the five companies explicitly reference biotechnology and/or healthcare (UniXell Biotechnology, Jiaoying Medical, e-BLOT Life Sciences, Affinity), while the remaining entry is classified as advanced materials/manufacturing (Guoquangzi). On stage, Series A appears in three entries (e-BLOT Life Sciences 2026-07-13; UniXell Biotechnology 2025-11-03; Jiaoying Medical 2025-10-17) versus Series B in two (Guoquangzi 2026-07-16; Affinity 2025-09-11), and every row is located in Pudong.
Most recent rounds
5 shownRelated listings
Frequently asked
Since all amounts are undisclosed, what can be inferred about relative deal size in Pudong from these five rows?
No disclosed-dollar comparisons are possible here because every listed round is marked undisclosed, including Guoquangzi (Series B, 2026-07-16) and e-BLOT Life Sciences (Series A, 2026-07-13). Any “largest” or “next-largest” analysis cannot be grounded in amounts for this page’s five entries.
Do these Pudong-funded rounds cluster more by date than by company?
Yes, the entries cluster within a single extended window from 2025-09-11 (Affinity) to 2026-07-16 (Guoquangzi). Three of the five rounds fall between 2025-10-17 and 2026-07-13 (Jiaoying Medical 2025-10-17, UniXell Biotechnology 2025-11-03, e-BLOT Life Sciences 2026-07-13).
Which sectors are over-represented among these five Pudong entries?
Life sciences/health appears in 4 of 5 companies: e-BLOT Life Sciences (genetics, Series A, 2026-07-13), UniXell Biotechnology (biotechnology/pharma/healthcare, Series A, 2025-11-03), Jiaoying Medical (healthcare, Series A, 2025-10-17), and Affinity (biotechnology/pharma, Series B, 2025-09-11). The remaining company is categorized outside that cluster as advanced materials/manufacturing (Guoquangzi, Series B, 2026-07-16).
What stage mix dominates these Pudong rounds, based on the labels shown?
Series A dominates with 3 of 5 entries (e-BLOT Life Sciences 2026-07-13, UniXell Biotechnology 2025-11-03, Jiaoying Medical 2025-10-17). Series B accounts for the other 2 of 5 entries (Guoquangzi 2026-07-16 and Affinity 2025-09-11).
Are there any outliers in sectors or timing that stand out for further diligence?
Guoquangzi on 2026-07-16 is an outlier by sector versus the rest: it is labeled advanced materials/manufacturing, while the other four entries are centered on genetics/biotechnology/pharma/healthcare. Timing-wise, the newest two entries (Guoquangzi 2026-07-16 and e-BLOT Life Sciences 2026-07-13) are also much later than the mid-2025 rounds (Affinity 2025-09-11 and the late-2025 Series A cohort).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.